Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma

Background: Real-world evidence on the effectiveness of mepolizumab in children and adolescents with severe asthma (SA) is limited. Objective: We sought to evaluate mepolizumab's impact on the clinical and health care resource utilization (HCRU) burden of SA in children and adolescents. Methods: -agonist (SABA) canister use, and HCRU per patient-year (PPY) pre- and post-mepolizumab; risk ratios from log-binomial regression models compared proportions of patients with ≥1 OCS dispensings and ≥1 SABA canister dispensings between periods. Results: < .001). Conclusions: Mepolizumab initiation was associated with significant reductions in asthma exacerbations, OCS and SABA use, and HCRU in children and adolescents with SA, demonstrating real-world clinical benefit.